secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2026-08-11T20:05:15+00:00
Accession:  0001193125-26-344580
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports Q2 2026 operating loss of $8.4M; cash $18.1M funds into Q1 2027
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $18.1M as of Jun 30, 2026; expected to fund operations into 1Q 2027.
- Collaboration revenue $5K vs $1.8M in Q2 2025; R&D expenses $5.1M vs $7.5M; G&A $2.4M vs $3.5M.
- Loss from operations $8.4M in Q2 2026 vs $9.2M in Q2 2025, driven by restructuring-related cost reductions.
- BDC-4182 Phase 1/2 in gastric/GEJ cancer ongoing; Cohort 4 dosing at 4.0 mg/kg; initial data expected with 3Q 2026 results.
- CEO Willie Quinn cites well-tolerated profile and activity consistent with immune-stimulating mechanism for BDC-4182.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/0001193125-26-344580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/bolt-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer